[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371511-105":59,"doc-detail-371511-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-population-survival-kinetics-assessment-of-extensive-small-cell-lung-cancer-and-rationale-for-maintenance-therapy","A Population Survival Kinetics Assessment of Extensive Small Cell Lung Cancer and Rationale for Maintenance Therapy","","Progression-free survival (PFS) and overall survival (OS) curves generally approximate first-order kinetics. On log-linear plots, convex curves with downward inflection can indicate late acceleration of progression or death, potentially related to stopping effective therapies. Published PFS/OS curves for extensive small-cell lung cancer (SCLC) treated with etoposide/platinum and other malignancies were digitized and replotted log-linearly. Results showed SCLC PFS and OS curves were highly or moderately convex far more often than other cancers, suggesting chemotherapy sensitivity followed by rapid progression after first-line completion. Maintenance strategies are needed.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-population-survival-kinetics-assessment-of-extensive-small-cell-lung-cancer-and-rationale-for-maintenance-therapy/371511/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-population-survival-kinetics-assessment-of-extensive-small-cell-lung-cancer-and-rationale-for-maintenance-therapy/371511.png","ImageObject",300,407,{"name":92,"@type":93},"Aria Callaghan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the study examine about survival curves in extensive small-cell lung cancer (SCLC)?","Question",{"text":112,"@type":113},"It evaluates whether PFS and OS curves follow first-order kinetics using log-linear replotting to assess curve shape and inflection patterns.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What patterns did the study find in SCLC progression-free survival (PFS) and overall survival (OS) curves?",{"text":117,"@type":113},"SCLC PFS curves were predominantly convex with late downward turn behavior, and all SCLC OS curves showed moderate or high convexity compared with other cancers.",{"name":119,"@type":110,"acceptedAnswer":120},"How do the authors interpret the convexity and inflection behavior in relation to treatment and maintenance therapy?",{"text":121,"@type":113},"They suggest convexity with specific inflection points may reflect subpopulations with different progression or death rates and that stopping effective therapy can lead to acceleration, supporting the need for effective maintenance strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371511,1790906464,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article  \nA Population Survival Kinetics Assessment of Extensive Small Cell Lung Cancer and Rationale for Maintenance Therapy  \nDavid J. Stewart *, Katherine Cole  and Stephanie Brule  \nReceived: 5 March 2025  \nRevised: 21 April 2025  \nAccepted: 27 April 2025  \nPublished: 29 April 2025  \nCitation: Stewart, D.J.; Cole, K.; Brule, S. A Population Survival Kinetics Assessment of Extensive Small Cell Lung Cancer and Rationale for Maintenance Therapy. Curr. Oncol. 2025, 32, 258. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/curroncol32050258](10.3390/curroncol32050258)  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \nFaculty of Medicine, Department of Medicine, Division of Medical Oncology, University of Ottawa, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada; [katcole@toh.ca](katcole@toh.ca) (K.C.); [sbrule@toh.ca](sbrule@toh.ca) (S.B.)  \n* Correspondence: [dstewart@toh.ca](dstewart@toh.ca); Tel.: +1-613-737-7700  \nAbstract: Progression-free survival (PFS) and overall survival (OS) curves generally approximate first-order kinetics. On log-linear plots, convex curves with downward inflection (indicating late acceleration of progression/death) might arise from stopping effective therapies. We digitized published PFS/OS curves for etoposide/platinum-treated extensive small-cell lung cancer (SCLC) and other malignancies and replotted the curves log-linearly. Of 26 SCLC PFS curves, 21 (81%) were highly convex (with a marked late down-turn), and 26 (100%) were moderately or highly convex vs. 35/888 (4%) highly convex and 186 (21%) moderately/highly convex curves for other cancers (p \u003C 0.0001) . For SCLC, all 32 OS curves were moderately or highly convex vs. 87/363 (24%) that were moderately/highly convex for other cancers (p \u003C 0.0001) . The SCLC PFS curves had an initial downward inflection at a median of 3.1 months (around the completion of first-line chemotherapy), then a second inflection at 5.4 months, with further acceleration of progression. The median PFS half-life was 11.9 months while receiving treatment vs. 1.7 months after the second inflection point. Immunotherapy benefit appeared to be limited to 6–10% of the population. SCLC PFS/OS curves are more often convex than for other cancers, reflecting SCLC chemotherapy sensitivity but rapid progression following the completion of first-line chemotherapy. Effective maintenance strategies are needed.  \nKeywords: population survival kinetics; small cell lung cancer; chemotherapy; PD-1/PDL1 inhibitors; overall survival; progression-free survival  \n1. Introduction  \nSmall-cell lung cancer (SCLC) grows rapidly. Without chemotherapy, median life expectancy is about 6 weeks for patients with extensive stage disease (i.e., patients with stage M1 disease) and 3 months for patients with limited stage disease (i.e., patients with stage M0 disease) [1] . However, SCLC is also sensitive to chemotherapy, with rapid clinical improvement and high response rates of 50–85% in the first-line setting [2] . The median life expectancy for extensive SCLC patients treated with chemotherapy is 8–12 months [2] . The combination of a platinum (cisplatin or carboplatin) withetoposide is the most commonly used regimen for SCLC, although other regimens such as irinotecan–cisplatin and cyclophosphamide/doxorubicin/vincristine (CAV) have similar activity [2] .  \nTypically, 4–6 cycles of first-line chemotherapy are given, followed by a break, with the option of restarting chemotherapy upon tumor regrowth [2] . Some trials have suggested an OS benefit from increasing the number of cycles of first-line chemotherapy [3,4], while others have shown only a modest impact on PFS and not OS [5] or an OS impact only  \nin ","cbCaitk3foXAcxVv","https://ap.wps.com/l/cbCaitk3foXAcxVv","pdf",954310,18,"English","# Abstract\n# 1. Introduction\n## First-order kinetics and survival curves\n## Log-linear plotting and clinical insight","[{\"question\":\"What does the study examine about survival curves in extensive small-cell lung cancer (SCLC)?\",\"answer\":\"It evaluates whether PFS and OS curves follow first-order kinetics using log-linear replotting to assess curve shape and inflection patterns.\"},{\"question\":\"What patterns did the study find in SCLC progression-free survival (PFS) and overall survival (OS) curves?\",\"answer\":\"SCLC PFS curves were predominantly convex with late downward turn behavior, and all SCLC OS curves showed moderate or high convexity compared with other cancers.\"},{\"question\":\"How do the authors interpret the convexity and inflection behavior in relation to treatment and maintenance therapy?\",\"answer\":\"They suggest convexity with specific inflection points may reflect subpopulations with different progression or death rates and that stopping effective therapy can lead to acceleration, supporting the need for effective maintenance strategies.\"}]","A Population Survival Kinetics Assessment of Extensive Small Cell Lung Cancer and Rationale for Maintenance Therapy | PDF",1790192236,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d480b69ba01aef433b9f3eb081091bca.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2954572029599a3190ec03e84c5ad916.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15431d714f3c741dc1a959e11b3ab7ee.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e1da3ff33e5ac359084897a010daa41.webp",980,1385]